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Efavirenz is a reverse transcriptase non analog nucleoside inhibitor used to treat HIV infections. A simple 
assay method by high performance liquid chromatography was developed and validated for efavirenz 
tablets. The physical chemical characteristics of efavirenz were investigated to developing the method. 
The method was validated observing the parameters described in USP 29. Analyses were performed 
by an ultraviolet detector at a 252 nm wavelength, on a reverse-phase column (C18, 250 mm x 3.9 mm, 
10 µm), using an isocratic mobile phase containing acetonitrile/water/orthophosphoric acid (70:30:0.1). 
The validation parameters used were: selectivity, linearity, precision, accuracy, robustness, detection and 
quantification limits, and all resulting data were treated by a statistical method. The results obtained 
confirmed an alternative assay method for efavirenz tablets adequate for routine industrial use.
Uniterms: Efavirenz/tablet assay. High performance liquid chromatography/quantitative analysis.
O efavirenz é um inibidor não análogo de nucleosídeo da transcriptase reversa, utilizado no tratamento 
da infecção por HIV. Um método simples, por cromatografia líquida de alta eficiência, foi desenvolvido 
e validado para quantificação do efavirenz em comprimidos. O desenvolvimento do método levou em 
consideração as características físico-químicas do efavirenz. O método foi validado seguindo os parâmetros 
da USP 29. A análise foi realizada por meio de detector ultravioleta, utilizando um comprimento de onda 
de 252 nm, com coluna de fase reversa (C18, 250 mm x 3.9 mm, 10 µm) e fase móvel isocrática contendo 
acetonitrila/água/ácido ortofosfórico (70: 30: 0.1). Os critérios usados para validação foram: seletividade, 
linearidade, precisão, exatidão, robustez e limites de detecção e quantificação do método. Foi utilizado 
método estatístico em todas as etapas do processo de validação. Os resultados obtidos mostraram que o 
método é uma alternativa para quantificação do efavirenz em comprimidos, tornando viável seu uso na 
rotina industrial e laboratórios analíticos.
Unitermos: Efavirenz/determinação em comprimidos. Cromatografia líquida de alta eficiência/análise 
quantitativa.
INTRODUCTION
Efavirenz is an antiretroviral agent employed in the 
treatment of HIV infections. It is a non analog nucleoside 
antiretroviral and non competitive reverse transcriptase 
inhibitor. Efavirenz is directly connected to the enzyme 
and blocks RNA and DNA-dependent, DNA-polymerase 
activities, causing destruction of the enzyme catalytic site. 
It has a molecular form of C14H9ClF3NO2, and is optically 
active with a molecular weight of 315.68. This crystalline 
powder has a white or slightly yellowish appearance. The 
substance has a melting point ranging from 136.0 ºC to 
141 ºC, is nearly water insoluble but is soluble in methanol 
and dichloromethane (Clercq, 2001).
Although several published analytic methods exist, 
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the majority seek to determine efavirenz by the HPLC 
technique associated with other antiretroviral drugs or 
their metabolites in biological fluids (Sarasa-Nacenta et 
al., 2001; Matthews et al., 2002).
For pharmaceutical forms, Montgomery and col-
laborators (2001) used reverse phase chromatography to 
analyze efavirenz and the impurities present in raw mate-
rial and capsules. In the cited study, the authors used a 
cyan column and a gradient mobile phase, with different 
proportions of methanol, water, and trifluoroacetic acid, 
and a 40-min run time. However, we sought to develop 
a method in order to facilitate the pharmaceutical indus-
try’s quality control routine, and thus should combine fast 
analyses with reliable results.
The present study describes the development and 
validation of an analytical assay method for efavirenz raw 
material and tablets by HPCL. The isocratic method was 
used together with a reverse-phase C18 column, acetonitrile 
mobile phase and water acidified with orthophosphoric 
acid, and a 7 min run time, according to the parameters 
described in USP 29 (2006) and ICH (2005). The method 




The previously described chromatographic system 
comprised: Class VP (Shimadzu®) HPLC, Membrane Degas-
ser, LC-10ADVP pumps, SIL-10ADVP self-injector, SPD-10 
AVP detector, SCL-10 AVP controller, and CTO-10ASVP 
oven; C18 column (Lichcrocart
®) 250 x 4 mm (10 µm) and C8 
column (Symmetry Waters®) 250 x 4.6 mm (5 µm).
Materials
The Efavirenz 600 mg coated tablet was develo-
ped in Pernambuco State Pharmaceutical Laboratory 
(LAFEPEÒ), and has the following composition: efavi-
renz (Hetero Labs®, EF0230703); sodium sulfate lauryl 
(Nuclear®); hydroxypropylcellulose (Denver®); cellulose 
microcrystalline 250 and 101 (Blanver®); polyvinylpyr-
rolidone (Xiamem®); crospovidone (ISP Technologies®); 
croscarmellose (Rellance celulose®); magnesium esterase 
(Blanver®); colloidal silicon dioxide (Henkel®), opadry 
Y-1-7000 (ColorconÒ). The placebo used in the validation 
study was prepared with excipients only.
The following reagents were used: HPLC-grade 
acetonitrile (ACN) (JT Baker®), HPLC-grade methanol 
(JT Baker®), orthophosphoric acid (H3PO4) at 85% for 
analysis (Merck®). The purified water used was obtained 
using the reverse osmosis system (Milli-Q Millipore 
Corporation®).
Chromatographic conditions
The chromatographic conditions used to validate 
the dosage method for efavirenz, substance and finished 
product, were as follows: isocratic system with a mobile 
phase made up of ACN: water: 85% H3PO4 (70:30:0.1); 
flow of 1.0 mL.min-1; oven temperature of 30 ºC; injec-
tion volume of 20 mL; λ = 252 nm; a C18 250 x 4 mm (10 
µm) column. The asymmetry factor (As) was calculated 
as 10% of the height of the chromatographic band (Sny-
der et al., 1997).
Standard solution preparation
Efavirenz supplied by Hetero Labs (lot WS.EF0202, 
with 99.93% purity), substance chemical reference (SQR), 
was used for standard solution preparation. The efavirenz 
standard stock solution was prepared in a mobile phase 
ACN/water/85% H3PO4 (70:30:0.1), at a concentration of 
400 mg.mL-1. Dilutions with mobile phase were performed 
in order to obtain solutions with concentrations between 
10 and 40 µg.mL-1, where an average concentration of 
20 mg.mL-1 was defined as 100%.
Analytical method development
Different columns, mobile phase, flow, and column 
temperatures were tested in the development of the analyti-
cal method. C8 and C18 columns of the same length and 
diameter were also tested, keeping the same parameters 
and conditions (1 mL.min-1 flow, mobile phase, injection 
volume of 20 mL, temperature 30 ºC). For the mobile 
phase, methanol/water, ACN/water and ACN/water/85% 
H3PO4 mixtures were tested, with the other parameters 
kept constant. The mobile phase holdup time, resolution, 
efavirenz peak asymmetry, and quantity of fractions defi-
ned by the reading of area integrations from the chromato-
grams were assessed. The concentration of tested samples 
was 20 mg.mL-1 throughout method development.
Validation study
For the process of defining the performance of the 
chromatographic system used, the following parameters 
were assessed: robustness, linearity, variation range, pre-
cision, accuracy, selectivity, detection and quantification 
limits for raw material and tablets.
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Robustness
The method’s robustness represented a measure of 
its ability to resist change in response to minor and delibe-
rate variations in analytical parameters (ICH, 2005). Ro-
bustness was determined based on temperature variations, 
mobile phase proportion, flow, and different acetonitrile 
manufacturers (robustness for finished product assessed). 
The analyses were performed in sextuplicate.
Linearity
Linearity denotes the ability of the method to pro-
vide results directly proportional to the concentration of 
substance in question within a given application range 
(Swartz, Krull, 1998; ICH, 2005; USP, 2006). The me-
thod linearity was assessed by linear regression analysis 
using the least-squares methods for the average points 
of three authentic calibration curves, at concentrations 
of 10, 15, 20, 25, 30 and 40 mg.mL-1. The variation 
range tested was 50-150% of analysis concentration. 
Linear model adjustment and regression validity tests 
were performed in order to check regression equation 
significance.
Precision
The method precision was assessed on two levels: 
repeatability and intermediate precision. The method 
was tested for these two precision levels based on 6 de-
terminations (ICH, 2005) at 20 mg.mL-1 concentrations. 
Intermediate precision was determined on different days 
by different analysts. Repeatability was expressed by the 
coefficient of variation (CV), whereas intermediate pre-
cision was expressed as CV and average reliance interval 
by Student’s t test (Ribani et al., 2004).
Accuracy
The method accuracy was assessed at three con-
centration levels: 40, 100 and 160% for raw material, 
where 100% corresponded to 20 µg.mL-1. In tablets, the 
evaluation was performed at concentrations of 70, 100 
and 130%, which were incorporated into a given amount 
of placebo. The tests for both the raw material and tablets 
were conducted in sextuplicate for each concentration le-
vel and were assessed using Student’s t test by comparing 
results obtained against theoretical values defined for each 
analyzed concentration.
Selectivity
To determine selectivity, the analyte was compared 
to placebo solution, verifying that no interference exists 
between the formulation excipients in the analysis method 
(Swartz, Krull, 1998; Ribani et al., 2004).
RESULTS AND DISCUSSION
Analytical method development 
Despite presenting similar characteristics and 
behavior, a significant difference in the mobile phase 
holdup time using the C8 and C18, columns was ob-
served, being shorter in the latter. On the tests with a 
mobile phase, no significant difference was observed 
between the results obtained with the mobile phase aci-
dified with orthophosphoric acid and the mobile phase 
without acidification. However, the acidified mobile 
phase provides for better separation of probable syn-
thesis impurities from the efavirenz, reducing the risks 
of interaction with other peaks. 
The mobile phase made up of methanol and water 
at a (60:40) proportion produced efavirenz precipitation 
inside the column, although good results were obtained 
at 70:30 and 80:20 proportions. The mobile phase cho-
sen for analytical method validation consisted of ACN/ 
water/ 85% H3PO4 (70:30:0.1), presented a mobile phase 
holdup time of 5.08 min, ease of manipulation, with good 
resolution and peak definition in the chromatogram. Tests 
were performed using the mobile phase and column 
defined, with the efavirenz being submitted to tempera-
tures of 40 ºC and 80 ºC to assess the analyte behavior 
under these conditions. There was no variation in the 
integration of peak areas obtained at these temperatures, 
where a reduction occurred only within the mobile phase 




The linear regression equation obtained by the 
proposed method using three authentic calibration curves 
was, y = 56456.61x + 245.033, where y represents the in-
tegrated peak area in the chromatogram, and x represents 
efavirenz concentration in µg.mL-1.
The correlation coefficient obtained of 0.99997 
demonstrates the good quality of the calibration curve, as 
the lower the dispersion of the set of points, the lower the 
uncertainty of the estimated regression coefficients. Using 
variance analysis, the model validation and the statistical 
significance of the adjusted curve can be tested. The data 
variance analysis demonstrated that the method is linear 
within the tested concentration range (10-40 µg.mL-1), and 
that there is no lack of model adjustment, as the calculated 
F (0.92) is lower than the listed F (3.26), evidencing that 
the assumption of lack of adjustment is false.
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Robustness
 The results for temperature robustness, mobile 
phase proportion, and acetonitrile supplier for the finished 
product dosage method, were statistically treated and are 
described in Table II. The method proved to be robust for 
the variations in the column temperature and mobile phase 
proportion assessed. The results of the variance analysis 
of Student’s t test for assessed parameters showed no sta-
tistically significant difference between the variations in 
temperature and mobile phase proportion or the acetoni-
trile manufacturers assessed, with a 95% reliance interval.
Precision: Finished Product
·	 Repeatability: Method repeatability can be ob-
served with a standard sampling deviation of 0.05% and 
a variation coefficient of 0.25%.
·	 Intermediate Precision: The intermediate preci-
sion results for the finished product showed the variation 
coefficient to be lower than 2% in all instances . On the 
significance tests assessing the method precision test 
results for the coated tablets analyzed, no statistically sig-
nificant differences among average values between days 
or between analysts was found. The calculated t was 0.53; 
1.80; 2.04 and 0.16 for between analysts day 1; between 
analysts day 2; between days analyst 1 and between days 
analyst 2, respectively, with all values lower than the cri-
tical t (2.23).
Accuracy
The results of the method accuracy study yielded 
a CV of 1.4; 0.61 and 0.53% for the theoretical concen-
trations of 70, 100 and 130%, respectively. A statistical 
significance analysis was conducted using Student’s t test. 
The calculated t was 0.22; 1.04; 2.46 respectively, with all 
values lower than the critical t (2.57).
In Figure 1, an efavirenz chromatogram obtained 
under chromatographic conditions shows a single well-
defined peak of efavirenz, with a 1.1 asymmetry. Based 
on the data observed from the method accuracy study, no 
statistically significant difference was found, with a 95% 
TABLE I - Composition definition of the mobile phase and column for validation
Column Mobile Phase % tR (min) Area AS
C18 ACN/ H20 60:40 8.56 1112004 1.26
C18 ACN/ H20 70:30 5.18 1110985 1.33
C8 ACN/ H20 70:30 7.24 1104365 1.28
C18 ACN/ H20 80:20 3.68 1096213 1.24
C18 ACN/ H20/85% H3PO4 60:40:0.1 8.52 1109042 1.18
C18 ACN/ H20/ 85% H3PO4 70:30:0.1 5.08 1128041 1.15
C18 ACN/ H20/ 85% H3PO4 80:20:0.1 3.70 1114729 1.19
C18 MeOH/H20 60:40 low solubility - -
C18 MeOH/H20 70:30 4.85 1107448 1.23
C18 MeOH/H20 80:20 3.77 1110316 1.31
Study of increased temperature in the chromatogram resolution
Column Mobile Phase % tR (min) Area AS
C18
ACN/H20/ 85% H3PO4 
at 40 ºC
70:30:0.1 3.74 1119299 1.23
C18
ACN/H20/ 85% H3PO4 
at 80 ºC
70:30:0.1 4.53 1118568 1.28
TABLE II - Finished product statistical study
PARAMETERS F cal. P value F critical t cal. t critical
Temperature (ºC) 0.14 0.87 3.68 - -
Mobile phase (ACN/H20 acidif.) 3.37 0.06 3.68 - -
ACN Manufacturer - - - 0.15 2.23
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reliance interval, between the obtained results and the 
defined theoretical values, showing that the method for 
determination of the efavirenz in tablets is accurate.
Selectivity
Comparison of the chromatograms obtained for the 
placebo solution and efavirenz tablets revealed no signifi-
cant interference of formulation excipients for the mobile 
phase holdup time of 5.08 min, using the same chroma-
tographic conditions for both samples. Figure 2 depicts 
chromatograms of placebo and efavirenz tablets showing 
that the method is selective for the analyte concerned.
CONCLUSION
The method presented proved to be a straight-
forward alternative assay for efavirenz raw material and ta-
blets, being robust, linear, precise, accurate, and selective, 
with well-defined peak reproduction and good resolution. 
The method developed therefore represents an alterna-
FIGURE 1 - Representative chromatogram obtained with the method precision
FIGURE 2 – Efavirenz Tablet chromatogram obtained for selectivity parameter
tive method in the laboratory routine of pharmaceutical 
industries, particularly those developing and producing 
anti-retroviral medications. The results obtained showed 
that the method complies with good laboratory practice 
requirements and meets the validation criteria set forth in 
USP and ICH guidelines.
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